Biodexa Provides Update On Progression Free, Overall Survival In Phase 1 Study Of MTX110 In Recurrent Glioblastoma
Biodexa Provides Update On Progression Free, Overall Survival In Phase 1 Study Of MTX110 In Recurrent Glioblastoma
MAGIC-G1 is an open-label, dose escalation study designed to assess the feasibility and safety of intermittent infusions of MTX110 administered by convection enhanced delivery (CED) via implanted refillable pump and catheter. Patients received MTX110 via intermittent repeated CED infusions. As of today, the status of patients in Cohort A is as follows:
MAGIC-G1是一項開放標籤，劑量遞增研究，旨在評估經過植入式可供補充的泵和導管通過傳導增強輸送（CED）間歇性輸入MTX110的可行性和安全性。患者通過間歇性重複的CED輸注接受了MTX110。截至今天，A組患者的狀況如下：
Patients #1 and #2 have deceased with overall survival (OS) since start of treatment of 12 months and 13 months, respectively.
患者#1和#2在開始治療後分別存活12個月和13個月，已經去世。
Patients #3 and #4 remain in post-study follow-up. Patient #3 had progression free survival (PFS) of six months and OS thus far of 13 months since start of treatment. Patient #4 has not yet had confirmed progression and, as of today, has PFS and OS of 12 months since start of treatment.
患者#3和#4仍在研究後隨訪中。從治療開始至今，患者#3的無進展生存（PFS）爲六個月，迄今爲止的總生存（OS）爲13個月。患者#4尚未確認疾病進展，截至今日，治療開始後患者#4的PFS和OS分別爲12個月。
